Colistimethate sodium inj
Products billed under this code include Colistimethate Sodium.
Payment limit per 150 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Colistimethate Sodium.
Payment limit per 150 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Colistimethate Sodium | Hikma Pharmaceuticals Usa Inc. | 00143-9443-01 | 1 | $18.051 |
| Colistimethate Sodium | Hikma Pharmaceuticals Usa Inc. | 00143-9443-12 | 12 | $216.612 |
| Colistimethate Sodium | Heritage Pharmaceuticals Inc. | 23155-0193-31 | 1 | $18.051 |
| Colistimethate Sodium | Heritage Pharmaceuticals Inc. | 23155-0193-41 | 12 | $216.612 |
| Colistimethate Sodium | Endo USA, Inc. | 42023-0107-01 | 1 | $18.051 |
| Colistimethate Sodium | Endo USA, Inc. | 42023-0131-06 | 6 | $108.306 |
| Colistimethate Sodium | FreseniUS Kabi USA, LLC | 63323-0393-06 | 1 | $18.051 |
| Colistimethate Sodium | Xellia Pharmaceuticals USA, LLC. | 70594-0023-01 | 1 | $18.051 |
| Colistimethate Sodium | Xellia Pharmaceuticals USA, LLC. | 70594-0023-04 | 12 | $216.612 |
| Colistimethate Sodium | Xellia Pharmaceuticals USA, LLC. | 70594-0023-09 | 1 | $18.051 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $18.051 | +$3.557 | 150 MG | Colistimethate sodium inj | v1, posted September 17, 2026 |
| 3Q26 | $14.494 | +$0.226 | 150 MG | Colistimethate sodium inj | v1, posted September 15, 2026 |
| 2Q26 | $14.268 | +$2.188 | 150 MG | Colistimethate sodium inj | v1, posted September 15, 2026 |
| 1Q26 | $12.08 | −$0.98 | 150 MG | Colistimethate sodium inj | v1, posted September 15, 2026 |
| 4Q25 | $13.06 | +$1.671 | 150 MG | Colistimethate sodium inj | v1, posted September 8, 2026 |
| 3Q25 | $11.389 | −$0.553 | 150 MG | Colistimethate sodium inj | v1, posted March 10, 2026 |
| 2Q25 | $11.942 | −$0.219 | 150 MG | Colistimethate sodium inj | v1, posted March 10, 2026 |
| 1Q25 | $12.161 | −$0.121 | 150 MG | Colistimethate sodium inj | v1, posted December 19, 2025 |
| 4Q24 | $12.282 | +$1.385 | 150 MG | Colistimethate sodium inj | v1, posted June 11, 2025 |
| 3Q24 | $10.897 | −$1.944 | 150 MG | Colistimethate sodium inj | v1, posted June 11, 2025 |
| 2Q24 | $12.841 | −$1.075 | 150 MG | Colistimethate sodium inj | v1, posted March 11, 2025 |
| 1Q24 | $13.916 | +$0.038 | 150 MG | Colistimethate sodium inj | v1, posted December 19, 2024 |
| 4Q23 | $13.878 | +$1.596 | 150 MG | Colistimethate sodium inj | v1, posted October 10, 2024 |
| 3Q23 | $12.282 | −$3.32 | 150 MG | Colistimethate sodium inj | v1, posted June 5, 2024 |
| 2Q23 | $15.602 | −$0.182 | 150 MG | Colistimethate sodium inj | v1, posted February 23, 2024 |
| 1Q23 | $15.784 | +$1.134 | 150 MG | Colistimethate sodium inj | v1, posted December 6, 2023 |
| 4Q22 | $14.65 | −$0.517 | 150 MG | Colistimethate sodium inj | v1, posted June 22, 2023 |
| 3Q22 | $15.167 | −$0.517 | 150 MG | Colistimethate sodium inj | v1, posted June 9, 2023 |
| 2Q22 | $15.684 | +$1.547 | 150 MG | Colistimethate sodium inj | v1, posted December 14, 2022 |
| 1Q22 | $14.137 | −$1.639 | 150 MG | Colistimethate sodium inj | v1, posted June 8, 2022 |
| 4Q21 | $15.776 | −$0.361 | 150 MG | Colistimethate sodium inj | v1, posted June 2, 2022 |
| 3Q21 | $16.137 | −$0.23 | 150 MG | Colistimethate sodium inj | v1, posted June 2, 2022 |
| 2Q21 | $16.367 | +$2.517 | 150 MG | Colistimethate sodium inj | v1, posted March 1, 2022 |
| 1Q21 | $13.85 | – | 150 MG | Colistimethate sodium inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.